Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2006 Dec 28;12(48):7725-36.
doi: 10.3748/wjg.v12.i48.7725.

New insights into the coagulopathy of liver disease and liver transplantation

Affiliations
Review

New insights into the coagulopathy of liver disease and liver transplantation

M Senzolo et al. World J Gastroenterol. .

Abstract

The liver is an essential player in the pathway of coagulation in both primary and secondary haemostasis. Only von Willebrand factor is not synthetised by the liver, thus liver failure is associated with impairment of coagulation. However, recently it has been shown that the delicate balance between pro and antithrombotic factors synthetised by the liver might be reset to a lower level in patients with chronic liver disease. Therefore, these patients might not be really anticoagulated in stable condition and bleeding may be caused only when additional factors, such as infections, supervene. Portal hypertension plays an important role in coagulopathy in liver disease, reducing the number of circulating platelets, but platelet function and secretion of thrombopoietin have been also shown to be impaired in patients with liver disease. Vitamin K deficiency may coexist, so that abnormal clotting factors are produced due to lack of gamma carboxylation. Moreover during liver failure, there is a reduced capacity to clear activated haemostatic proteins and protein inhibitor complexes from the circulation. Usually therapy for coagulation disorders in liver disease is needed only during bleeding or before invasive procedures. When end stage liver disease occurs, liver transplantation is the only treatment available, which can restore normal haemostasis, and correct genetic clotting defects, such as haemophilia or factor V Leiden mutation. During liver transplantation haemorrage may occur due to the pre-existing hypocoagulable state, the collateral circulation caused by portal hypertension and increased fibrinolysis which occurs during this surgery.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Native-TEG (A) and heparinaseI-TEG (B) on sample collected at the onset of spontaneous bacterial peritonitis in a patient with liver liver cirrhosis. (A) significant heparin-like effect found revealed by the slowed rate of coagulation. (B) treatment of the sample with heparinaseIincreases the rate of coagulation, thus sampling the presence of heparin-like substances.

Similar articles

Cited by

References

    1. Lisman T, Leebeek FW, de Groot PG. Haemostatic abnormalities in patients with liver disease. J Hepatol. 2002;37:280–287. - PubMed
    1. Rapaport SI. Coagulation problems in liver disease. Blood Coagul Fibrinolysis. 2000;11 Suppl 1:S69–S74. - PubMed
    1. Tripodi A, Salerno F, Chantarangkul V, Clerici M, Cazzaniga M, Primignani M, Mannuccio Mannucci P. Evidence of normal thrombin generation in cirrhosis despite abnormal conventional coagulation tests. Hepatology. 2005;41:553–558. - PubMed
    1. Kelly DA, Summerfield JA. Hemostasis in liver disease. Semin Liver Dis. 1987;7:182–191. - PubMed
    1. Ferro D, Quintarelli C, Lattuada A, Leo R, Alessandroni M, Mannucci PM, Violi F. High plasma levels of von Willebrand factor as a marker of endothelial perturbation in cirrhosis: relationship to endotoxemia. Hepatology. 1996;23:1377–1383. - PubMed

MeSH terms